<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhao Y</submitter><funding>Conseil Régional de Picardie</funding><funding>Seventh Framework Programme</funding><funding>European Regional Development Fund</funding><pagination>5978-5987</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9049337</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(10)</volume><pubmed_abstract>Degradable molecularly imprinted polymers (MIPs) with affinity for &lt;i>S&lt;/i>-propranolol were prepared by the copolymerization of methacrylic acid as functional monomer and a disulfide-containing cross-linker, bis(2-methacryloyloxyethyl)disulfide (DSDMA), using bulk polymerization or high dilution polymerization for nanogels synthesis. The specificity and the selectivity of DSDMA-based molecularly imprinted polymers toward &lt;i>S&lt;/i>-propranolol were studied in batch binding experiments, and their binding properties were compared to a traditional ethylene glycol dimethacrylate (EDMA)-based MIP. Nanosized MIPs prepared with DSDMA as crosslinker could be degraded into lower molecular weight linear polymers by cleaving the disulfide bonds and thus reversing cross-linking using different reducing agents (NaBH&lt;sub>4&lt;/sub>, DTT, GSH). Turbidity, viscosity, polymer size and IR-spectra were measured to study the polymer degradation. The loss of specific recognition and binding capacity of &lt;i>S&lt;/i>-propranolol was also observed after MIP degradation. This phenomenon was applied to modulate the release properties of the MIP. In presence of GSH at its intracellular concentration, the &lt;i>S&lt;/i>-propranolol release was higher, showing that these materials could potentially be applied as intracellular controlled drug delivery system.</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Reduction-responsive molecularly imprinted nanogels for drug delivery applications.</pubmed_title><pmcid>PMC9049337</pmcid><funding_grant_id>Marie Curie Programme ITN CHEBANA</funding_grant_id><pubmed_authors>Falcimaigne-Cordin A</pubmed_authors><pubmed_authors>Daoud Attieh M</pubmed_authors><pubmed_authors>Haupt K</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Simon C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reduction-responsive molecularly imprinted nanogels for drug delivery applications.</name><description>Degradable molecularly imprinted polymers (MIPs) with affinity for &lt;i>S&lt;/i>-propranolol were prepared by the copolymerization of methacrylic acid as functional monomer and a disulfide-containing cross-linker, bis(2-methacryloyloxyethyl)disulfide (DSDMA), using bulk polymerization or high dilution polymerization for nanogels synthesis. The specificity and the selectivity of DSDMA-based molecularly imprinted polymers toward &lt;i>S&lt;/i>-propranolol were studied in batch binding experiments, and their binding properties were compared to a traditional ethylene glycol dimethacrylate (EDMA)-based MIP. Nanosized MIPs prepared with DSDMA as crosslinker could be degraded into lower molecular weight linear polymers by cleaving the disulfide bonds and thus reversing cross-linking using different reducing agents (NaBH&lt;sub>4&lt;/sub>, DTT, GSH). Turbidity, viscosity, polymer size and IR-spectra were measured to study the polymer degradation. The loss of specific recognition and binding capacity of &lt;i>S&lt;/i>-propranolol was also observed after MIP degradation. This phenomenon was applied to modulate the release properties of the MIP. In presence of GSH at its intracellular concentration, the &lt;i>S&lt;/i>-propranolol release was higher, showing that these materials could potentially be applied as intracellular controlled drug delivery system.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Feb</publication><modification>2025-04-04T08:20:59.074Z</modification><creation>2025-02-18T23:21:20.116Z</creation></dates><accession>S-EPMC9049337</accession><cross_references><pubmed>35497405</pubmed><doi>10.1039/c9ra07512g</doi></cross_references></HashMap>